In another study examining the role of SRF in hepatocellular carcinoma resistance to sorafenib, an oral multi-kinase inhibitor, Bae et al.5 showed that antisense inhibition of SRF expression in SH-J1 cells significantly enhances the apoptotic effects of sorafenib while reducing expression of mesenchymal markers and restoring expression of E-cadherin. The gene discussed is CDH1; the disease is hepatocellular carcinoma.